19-Mar-2025
Anti-amyloid drug shows signs of preventing Alzheimer’s dementia
WashU MedicinePeer-Reviewed Publication
An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest – for the first time in a clinical trial – that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.
- Journal
- The Lancet Neurology
- Funder
- NIH/National Institute on Aging, Alzheimer's Association, Eli Lilly and Company, F. Hoffman-LaRoche, Avid Radiopharmaceuticals, GHR Foundation, Cerveau Technologies, Cogstate and Signant, DIAN-TU Pharma Consortium